Total Funding
90
83
Total FundingSeries B raised
Growth Score
-7 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
703
Kailera Therapeutics develops next-generation injectable and oral therapies for chronic weight management.
- Ronald Renaud: CEO, President & FounderPast Role: Cerevel Therapeutics, President & CEO
- Doug Bakan: CTO
About the Company
Kailera Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic pipelines for obesity and type 2 diabetes. The pipeline includes injectable and oral peptides, such as GLP-1/GIP and GLP-1/GIP/Glucagon receptor agonists. Kailera Therapeutics licenses its therapies and conducts clinical trials focused on
delivering treatment options for chronic weight management.
